NYSEAMERICAN:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.62
-0.02 (-3.14 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.61
$0.64
50-Day Range
$0.32
$0.50
52-Week Range
$0.26
$1.70
Volume1.87 million shs
Average Volume14.02 million shs
Market Capitalization$81.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
30 days | 90 days | 365 days | Advanced Chart
Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter.


Synthetic Biologics logo

About Synthetic Biologics

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

479th out of 2,100 stocks

Pharmaceutical Preparations Industry

233rd out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Is Synthetic Biologics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Synthetic Biologics stock.
View analyst ratings for Synthetic Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than Synthetic Biologics?

Wall Street analysts have given Synthetic Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synthetic Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.11.
View Synthetic Biologics' earnings history
.

How has Synthetic Biologics' stock been impacted by COVID-19?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SYN shares have increased by 71.2% and is now trading at $0.6164.
View which stocks have been most impacted by COVID-19
.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics shares reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

1 analysts have issued 1-year price targets for Synthetic Biologics' shares. Their forecasts range from $1.50 to $1.50. On average, they anticipate Synthetic Biologics' stock price to reach $1.50 in the next year. This suggests a possible upside of 143.3% from the stock's current price.
View analysts' price targets for Synthetic Biologics
or view top-rated stocks among Wall Street analysts.

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 60, Pay $941.99k)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Ms. Lara M. Guzman, Sr. Director of Project Operations

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.78%), MSD Partners L.P. (0.73%), Geode Capital Management LLC (0.65%), UBS Group AG (0.44%), Citadel Advisors LLC (0.41%) and Virtu Financial LLC (0.35%).
View institutional ownership trends for Synthetic Biologics
.

Which institutional investors are buying Synthetic Biologics stock?

SYN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., MSD Partners L.P., Geode Capital Management LLC, UBS Group AG, Citadel Advisors LLC, Virtu Financial LLC, Northern Trust Corp, and tru Independence LLC.
View insider buying and selling activity for Synthetic Biologics
or or view top insider-buying stocks.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.62.

How much money does Synthetic Biologics make?

Synthetic Biologics has a market capitalization of $81.39 million.

How many employees does Synthetic Biologics have?

Synthetic Biologics employs 10 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

Where are Synthetic Biologics' headquarters?

Synthetic Biologics is headquartered at 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.